ECSP045479A - COMBINATIONS THAT INCLUDE EPOTILONES AND THEIR PHARMACEUTICAL USES - Google Patents
COMBINATIONS THAT INCLUDE EPOTILONES AND THEIR PHARMACEUTICAL USESInfo
- Publication number
- ECSP045479A ECSP045479A ECSP045479A ECSP045479A EC SP045479 A ECSP045479 A EC SP045479A EC SP045479 A ECSP045479 A EC SP045479A EC SP045479 A ECSP045479 A EC SP045479A
- Authority
- EC
- Ecuador
- Prior art keywords
- inhibitors
- combination
- treatment
- topoisomerase
- simultaneous
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 108010070753 Adenosylmethionine decarboxylase Proteins 0.000 abstract 1
- 102000005758 Adenosylmethionine decarboxylase Human genes 0.000 abstract 1
- 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 abstract 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 abstract 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 abstract 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 abstract 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 abstract 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 1
- 102000029749 Microtubule Human genes 0.000 abstract 1
- 108091022875 Microtubule Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940123924 Protein kinase C inhibitor Drugs 0.000 abstract 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 abstract 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000002280 anti-androgenic effect Effects 0.000 abstract 1
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 1
- 229940046836 anti-estrogen Drugs 0.000 abstract 1
- 230000001833 anti-estrogenic effect Effects 0.000 abstract 1
- 239000000051 antiandrogen Substances 0.000 abstract 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 239000003886 aromatase inhibitor Substances 0.000 abstract 1
- 229940046844 aromatase inhibitors Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003954 decarboxylase inhibitor Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 150000003883 epothilone derivatives Chemical class 0.000 abstract 1
- 239000000328 estrogen antagonist Substances 0.000 abstract 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 abstract 1
- 229960001442 gonadorelin Drugs 0.000 abstract 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 abstract 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000004688 microtubule Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003881 protein kinase C inhibitor Substances 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención se refiere a una combinación farmacéutica que comprende (a) un anticuerpo de HER-1 o HER-2, o (b) por lo menos un agente antineoplástico seleccionado del grupo que consiste de inhibidores de aromatasa, antiestrógenos, inhibidores de topoisomerasa I, inhibidores de topoisomerasa II, agentes activos de microtúbulo, inhibidores de cinasa C de proteína, compuestos anti-angiogénicos, agonistas de gonadorelina, anti-andrógenos, inhibidores de histona-desacetilasa e inhibidores de S-adenosil-metionina-descarboxilasa, y (c) un derivado de epotilona de la fórmula (I), y opcionalmente por lo menos un vehículo farmacéuticamente aceptable para uso simultáneo, separado o secuencial, en particular, para el tratamiento de una enfermedad proliferativa, especialmente una enfermedad de tumor sólido; una composición farmacéutica que comprende dicha combinación; el uso de dicha combinación para la preparación de un medicamento para el tratamiento de una enfermedad proliferativa; un paquete o producto comercial que comprende dicha combinación como una preparación combinada para uso simultáneo, separado o secuencial; y a un método para el tratamiento de un animal de sangre caliente, especialmente un ser humano.The invention relates to a pharmaceutical combination comprising (a) an HER-1 or HER-2 antibody, or (b) at least one antineoplastic agent selected from the group consisting of aromatase inhibitors, antiestrogens, topoisomerase I inhibitors , topoisomerase II inhibitors, active microtubule agents, protein kinase C inhibitors, anti-angiogenic compounds, gonadorelin agonists, anti-androgens, histone deacetylase inhibitors and S-adenosyl methionine decarboxylase inhibitors, and (c ) an epothilone derivative of the formula (I), and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular, for the treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition comprising said combination; the use of said combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising said combination as a combined preparation for simultaneous, separate or sequential use; and to a method for the treatment of a warm-blooded animal, especially a human being.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38702502P | 2002-06-10 | 2002-06-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP045479A true ECSP045479A (en) | 2005-01-28 |
Family
ID=35161211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP045479 ECSP045479A (en) | 2002-06-10 | 2004-12-08 | COMBINATIONS THAT INCLUDE EPOTILONES AND THEIR PHARMACEUTICAL USES |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP045479A (en) |
-
2004
- 2004-12-08 EC ECSP045479 patent/ECSP045479A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP077324A (en) | BICYCLIC AMIDAS AS INHIBITORS OF CINASA | |
| DE60333754D1 (en) | EPOTHILONE CONTAINING COMBINATIONS AND THEIR PHARMACEUTICAL USES | |
| MXPA05012573A (en) | Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors. | |
| AR046510A1 (en) | COMPOSITION OF A VEGF ANTAGONIST AND AN ANTI-PROLIFERATIVE AGENT | |
| BRPI0508540A8 (en) | COMPOUND, PHARMACEUTICAL COMPOSITION, AND, USE OF A COMPOUND | |
| UY29562A1 (en) | AMINO BENZOIL HETEROCYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCEDURES AND APPLICATIONS | |
| UY27943A1 (en) | COMPOSITIONS AND METHODS TO TREAT CRNCER USING ANTIBODY IMMUNOCATE PLAYS FOR CD44 CYTOTNXICS AND CHEMOTHERAPCUTIC AGENTS | |
| PA8606201A1 (en) | PIRROLO DERIVATIVES [3,4-c) PIRAZOL ASSETS AS QUINASE INHIBITORS, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM | |
| CL2009001160A1 (en) | Compounds derived from fused nitrogen heterocycles and their pharmaceutical composition. | |
| BR0316004A (en) | Pharmaceutical composition comprising a cdk and gemcitabine inhibitor | |
| ECSP094948A (en) | COMBINATIONS THAT INCLUDE EPOTILONES AND THEIR PHARMACEUTICAL USES | |
| GT200500307A (en) | CHEMICAL COMPOUNDS | |
| UY28271A1 (en) | CHEMICAL COMPOUNDS | |
| CY1116180T1 (en) | COMPOSITIONS OF SOMETHING PASTE | |
| AR056801A1 (en) | ANTI-PROLIFERATIVE COMBINED THERAPY WITH CERTAIN PLATINUM-BASED CHEMOTHERAPEUTIC AGENTS AND EGFR INHIBITORS OR PYRIMIDINE ANALOGS | |
| NO20055891L (en) | Quinazoline derivatives as aurorakinase inhibitors | |
| UY29561A1 (en) | DERIVATIVES OF QUINAZOLINE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PREPARATION PROCEDURES AND APPLICATIONS | |
| BR0307629A (en) | Methods and compositions for treating hyperproliferative conditions | |
| PE20040990A1 (en) | COMBINATIONS OF ERB B KINASE INHIBITORS AND ANTINEOPLASTIC DRUGS | |
| GT200500020A (en) | DERIVATIVES OF 1H-TIENO [2,3-C] PIRAZOL USEFUL AS QUINASE INHIBITORS. | |
| AR039895A1 (en) | COMPOSITION THAT INCLUDES A VITAMIN, A METAL SALT AND AN INSULIN OR A HORMONE OF THE GROWTH AND USE OF SUCH COMPONENTS TO PREPARE IT | |
| BR112013012994A2 (en) | long-acting, lipophilic and selective beta-agonist monotherapeutic formulations and methods for the cosmetic treatment of contour adiposity and overhang | |
| ECSP045479A (en) | COMBINATIONS THAT INCLUDE EPOTILONES AND THEIR PHARMACEUTICAL USES | |
| AU2011219546A1 (en) | Fungal nail treatment composition | |
| AR037496A1 (en) | NOVEDOUS USE OF 2- [5- (4-FLUOROPHENYL) -3-PIRIDILMETILAMINOMETIL] -CROMANO AND ITS PHYSIOLOGICALLY ACCEPTABLE SALTS |